Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens

Jennifer L. Kelly; Stephen R. Toothaker; Lauren Ciminello; Dieter Hoelzer; Harald Holte; Ann S. LaCasce; Graham Mead; Deborah Thomas; Gustaaf W. Van Imhoff; Brad S. Kahl; Bruce D. Cheson; Ian T. Magrath; Richard I. Fisher; Jonathan W. Friedberg

doi:10.3816/CLM.2009.n.060

Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens

Jennifer L. Kelly, Stephen R. Toothaker, Lauren Ciminello, Dieter Hoelzer, Harald Holte, Ann S. LaCasce, Graham Mead, Deborah Thomas, Gustaaf W. Van Imhoff, Brad S. Kahl, Bruce D. Cheson, Ian T. Magrath, Richard I. Fisher, Jonathan W. Friedberg^*

^*Corresponding author for this work

Faculty of Medical Sciences/UMCG

Research output: Contribution to journal › Article › Academic › peer-review

45 Citations (Scopus)

Abstract

Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens. The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years. Older patients have historically been underrepresented in published clinical trials of modern intensive therapy, and the outcome of these patients has not been systematically reported. We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature. Historically inferior outcomes of this age subgroup have improved substantially over time. We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma; (2) selected patients > age 40 now have highly favorable outcomes; and (3) future studies should include formal analysis of this subgroup of patients.

Original language	English
Pages (from-to)	307-310
Number of pages	4
Journal	Clinical lymphoma & myeloma
Volume	9
Issue number	4
DOIs	https://doi.org/10.3816/CLM.2009.n.060
Publication status	Published - Aug-2009

Keywords

HIV-negative acute lymphocytic leukemia
Non-Hodgkin lymphoma
Non-Hodgkin's lymphoma
Older patients
ACUTE-LYMPHOBLASTIC-LEUKEMIA
NON-HODGKIN-LYMPHOMA
ADULT BURKITT
CELL LYMPHOMA
HYPER-CVAD
PLUS RITUXIMAB
ADOLESCENTS
CHILDREN
THERAPY
TRIAL

Access to Document

10.3816/CLM.2009.n.060

Handle.net

Persistent link

Cite this

Kelly, J. L., Toothaker, S. R., Ciminello, L., Hoelzer, D., Holte, H., LaCasce, A. S., Mead, G., Thomas, D., Van Imhoff, G. W., Kahl, B. S., Cheson, B. D., Magrath, I. T., Fisher, R. I., & Friedberg, J. W. (2009). Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens. Clinical lymphoma & myeloma, 9(4), 307-310. https://doi.org/10.3816/CLM.2009.n.060

@article{1d8ae852a4934a96b5bfd821eee16126,

title = "Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens",

abstract = "Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens. The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years. Older patients have historically been underrepresented in published clinical trials of modern intensive therapy, and the outcome of these patients has not been systematically reported. We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature. Historically inferior outcomes of this age subgroup have improved substantially over time. We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma; (2) selected patients > age 40 now have highly favorable outcomes; and (3) future studies should include formal analysis of this subgroup of patients.",

keywords = "HIV-negative acute lymphocytic leukemia, Non-Hodgkin lymphoma, Non-Hodgkin's lymphoma, Older patients, ACUTE-LYMPHOBLASTIC-LEUKEMIA, NON-HODGKIN-LYMPHOMA, ADULT BURKITT, CELL LYMPHOMA, HYPER-CVAD, PLUS RITUXIMAB, ADOLESCENTS, CHILDREN, THERAPY, TRIAL",

author = "Kelly, {Jennifer L.} and Toothaker, {Stephen R.} and Lauren Ciminello and Dieter Hoelzer and Harald Holte and LaCasce, {Ann S.} and Graham Mead and Deborah Thomas and {Van Imhoff}, {Gustaaf W.} and Kahl, {Brad S.} and Cheson, {Bruce D.} and Magrath, {Ian T.} and Fisher, {Richard I.} and Friedberg, {Jonathan W.}",

year = "2009",

month = aug,

doi = "10.3816/CLM.2009.n.060",

language = "English",

volume = "9",

pages = "307--310",

journal = "Clinical lymphoma & myeloma",

issn = "1557-9190",

number = "4",

}

Kelly, JL, Toothaker, SR, Ciminello, L, Hoelzer, D, Holte, H, LaCasce, AS, Mead, G, Thomas, D, Van Imhoff, GW, Kahl, BS, Cheson, BD, Magrath, IT, Fisher, RI & Friedberg, JW 2009, 'Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens', Clinical lymphoma & myeloma, vol. 9, no. 4, pp. 307-310. https://doi.org/10.3816/CLM.2009.n.060

TY - JOUR

T1 - Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens

AU - Kelly, Jennifer L.

AU - Toothaker, Stephen R.

AU - Ciminello, Lauren

AU - Hoelzer, Dieter

AU - Holte, Harald

AU - LaCasce, Ann S.

AU - Mead, Graham

AU - Thomas, Deborah

AU - Van Imhoff, Gustaaf W.

AU - Kahl, Brad S.

AU - Cheson, Bruce D.

AU - Magrath, Ian T.

AU - Fisher, Richard I.

AU - Friedberg, Jonathan W.

PY - 2009/8

Y1 - 2009/8

N2 - Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens. The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years. Older patients have historically been underrepresented in published clinical trials of modern intensive therapy, and the outcome of these patients has not been systematically reported. We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature. Historically inferior outcomes of this age subgroup have improved substantially over time. We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma; (2) selected patients > age 40 now have highly favorable outcomes; and (3) future studies should include formal analysis of this subgroup of patients.

AB - Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens. The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years. Older patients have historically been underrepresented in published clinical trials of modern intensive therapy, and the outcome of these patients has not been systematically reported. We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature. Historically inferior outcomes of this age subgroup have improved substantially over time. We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma; (2) selected patients > age 40 now have highly favorable outcomes; and (3) future studies should include formal analysis of this subgroup of patients.

KW - HIV-negative acute lymphocytic leukemia

KW - Non-Hodgkin lymphoma

KW - Non-Hodgkin's lymphoma

KW - Older patients

KW - ACUTE-LYMPHOBLASTIC-LEUKEMIA

KW - NON-HODGKIN-LYMPHOMA

KW - ADULT BURKITT

KW - CELL LYMPHOMA

KW - HYPER-CVAD

KW - PLUS RITUXIMAB

KW - ADOLESCENTS

KW - CHILDREN

KW - THERAPY

KW - TRIAL

U2 - 10.3816/CLM.2009.n.060

DO - 10.3816/CLM.2009.n.060

M3 - Article

SN - 1557-9190

VL - 9

SP - 307

EP - 310

JO - Clinical lymphoma & myeloma

JF - Clinical lymphoma & myeloma

IS - 4

ER -

Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this